Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments.
Market
Pharmaceuticals
Location
Waltham,
MA,
USA
Coinvestors
Fidelity Management & Research Company, GV, Mithril Capital Management, Omega Funds, OrbiMed Advisors, Polaris Partners, Population Health Partners